Finance

Biopharma reports Q1 revenues of $0.7 million, net loss of $4.8 million

Published in Women's Health Weekly, June 10th, 2004

Genelabs Technologies, Inc., (GNLB) reported revenues of $0.7 million and a net loss of $4.8 million, or $0.05 per share for the first quarter 2004.

This compares to revenues of $0.7 million and a net loss of $4.2 million, or $0.08 per share for the first quarter 2003.

At March 31, 2004, Genelabs had $25.8 million in cash and short-term investments.

"During the first quarter of 2004 Genelabs made important progress in all facets of our business," stated James A.D. Smith, president and chief executive officer. "We completed enrollment into our confirmatory clinical trial of Prestara for lupus [systemic lupus erythematosus], entered...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2004-06-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry